Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates
ABSTRACT Trichomonas vaginalis is the most common non-viral sexually transmitted infection worldwide. We compared the in vitro activity of the thiazolide nitazoxanide (NTZ) and its metabolite, tizoxanide (TIZ), with the activity of the Food and Drug Administration-approved 5-nitroimidazoles (metroni...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2025-07-01
|
| Series: | Microbiology Spectrum |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/spectrum.02717-24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839645653322432512 |
|---|---|
| author | Keonte J. Graves John C. Williamson Jan Novak Hemant K. Tiwari W. Evan Secor Christina A. Muzny |
| author_facet | Keonte J. Graves John C. Williamson Jan Novak Hemant K. Tiwari W. Evan Secor Christina A. Muzny |
| author_sort | Keonte J. Graves |
| collection | DOAJ |
| description | ABSTRACT Trichomonas vaginalis is the most common non-viral sexually transmitted infection worldwide. We compared the in vitro activity of the thiazolide nitazoxanide (NTZ) and its metabolite, tizoxanide (TIZ), with the activity of the Food and Drug Administration-approved 5-nitroimidazoles (metronidazole [MTZ], tinidazole [TDZ], and secnidazole [SEC]) against MTZ-susceptible and MTZ-resistant Trichomonas vaginalis clinical isolates. Frozen, stored T. vaginalis clinical isolates (n = 36) were cultured in Diamond’s trypticase-yeast-maltose media supplemented with heat-inactivated horse serum and an antibiotic cocktail. Drug-susceptibility assays for the thiazolides (NTZ and TIZ) and the 5-nitroimidazoles (MTZ, TDZ, and SEC) were performed to determine the minimum lethal concentrations (MLCs) for each T. vaginalis isolate and the median MLC for each drug. Of the 36 T. vaginalis isolates cultured, 18 were MTZ resistant and 18 were MTZ susceptible. For the 18 MTZ-resistant strains, the median MLCs for MTZ, TDZ, and SEC were 100, 25, and 50 µg/mL, respectively. By contrast, the median MLCs for NTZ and TIZ were considerably lower at 1.6 and 0.8 µg/mL, respectively. The similarity in thiazolide MLCs in all T. vaginalis strains, regardless of sensitivity to MTZ, suggests that NTZ and TIZ act via a different mechanism than the 5-nitroimidazoles. Future investigations will focus on the in vivo activity of NTZ and TIZ as well as the efficacy of thiazolides used as monotherapy or as combination therapy, particularly in T. vaginalis-infected patients who do not respond to 5-nitroimidazole treatment.IMPORTANCEInvestigating drug resistance and alternative treatment options for Trichomonas vaginalis is crucial due to the increasing prevalence of persistent infections and the potential failure of standard therapies (i.e., 5-nitroimidazoles). Trichomoniasis can lead to significant health complications, including increased susceptibility to sexually transmitted infections and adverse pregnancy outcomes. The rise of 5-nitroimidazole drug-resistant strains poses a challenge to effective treatment, necessitating ongoing research to understand the mechanisms behind this resistance. Exploring alternative treatments, such as novel pharmacological agents like nitazoxanide and tizoxanide, could provide more effective options for managing these persistent infections. Additionally, comprehensive investigations can help inform public health strategies and reduce transmission rates. Ultimately, prioritizing research in this area is essential for improving patient outcomes and safeguarding reproductive health. |
| format | Article |
| id | doaj-art-a085192097f942f6b4aa08b5082a6dd3 |
| institution | Matheson Library |
| issn | 2165-0497 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | Microbiology Spectrum |
| spelling | doaj-art-a085192097f942f6b4aa08b5082a6dd32025-07-01T13:01:59ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972025-07-0113710.1128/spectrum.02717-24Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolatesKeonte J. Graves0John C. Williamson1Jan Novak2Hemant K. Tiwari3W. Evan Secor4Christina A. Muzny5Division of Infectious Diseases, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USADepartment of Internal Medicine, Section on Infectious Diseases, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USADepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USADepartment of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USADivision of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USADivision of Infectious Diseases, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USAABSTRACT Trichomonas vaginalis is the most common non-viral sexually transmitted infection worldwide. We compared the in vitro activity of the thiazolide nitazoxanide (NTZ) and its metabolite, tizoxanide (TIZ), with the activity of the Food and Drug Administration-approved 5-nitroimidazoles (metronidazole [MTZ], tinidazole [TDZ], and secnidazole [SEC]) against MTZ-susceptible and MTZ-resistant Trichomonas vaginalis clinical isolates. Frozen, stored T. vaginalis clinical isolates (n = 36) were cultured in Diamond’s trypticase-yeast-maltose media supplemented with heat-inactivated horse serum and an antibiotic cocktail. Drug-susceptibility assays for the thiazolides (NTZ and TIZ) and the 5-nitroimidazoles (MTZ, TDZ, and SEC) were performed to determine the minimum lethal concentrations (MLCs) for each T. vaginalis isolate and the median MLC for each drug. Of the 36 T. vaginalis isolates cultured, 18 were MTZ resistant and 18 were MTZ susceptible. For the 18 MTZ-resistant strains, the median MLCs for MTZ, TDZ, and SEC were 100, 25, and 50 µg/mL, respectively. By contrast, the median MLCs for NTZ and TIZ were considerably lower at 1.6 and 0.8 µg/mL, respectively. The similarity in thiazolide MLCs in all T. vaginalis strains, regardless of sensitivity to MTZ, suggests that NTZ and TIZ act via a different mechanism than the 5-nitroimidazoles. Future investigations will focus on the in vivo activity of NTZ and TIZ as well as the efficacy of thiazolides used as monotherapy or as combination therapy, particularly in T. vaginalis-infected patients who do not respond to 5-nitroimidazole treatment.IMPORTANCEInvestigating drug resistance and alternative treatment options for Trichomonas vaginalis is crucial due to the increasing prevalence of persistent infections and the potential failure of standard therapies (i.e., 5-nitroimidazoles). Trichomoniasis can lead to significant health complications, including increased susceptibility to sexually transmitted infections and adverse pregnancy outcomes. The rise of 5-nitroimidazole drug-resistant strains poses a challenge to effective treatment, necessitating ongoing research to understand the mechanisms behind this resistance. Exploring alternative treatments, such as novel pharmacological agents like nitazoxanide and tizoxanide, could provide more effective options for managing these persistent infections. Additionally, comprehensive investigations can help inform public health strategies and reduce transmission rates. Ultimately, prioritizing research in this area is essential for improving patient outcomes and safeguarding reproductive health.https://journals.asm.org/doi/10.1128/spectrum.02717-24Trichomonas vaginalisdrug resistancenitazoxanidetizoxanide5-nitroimidazole |
| spellingShingle | Keonte J. Graves John C. Williamson Jan Novak Hemant K. Tiwari W. Evan Secor Christina A. Muzny Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates Microbiology Spectrum Trichomonas vaginalis drug resistance nitazoxanide tizoxanide 5-nitroimidazole |
| title | Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates |
| title_full | Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates |
| title_fullStr | Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates |
| title_full_unstemmed | Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates |
| title_short | Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates |
| title_sort | nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole susceptible and metronidazole resistant trichomonas vaginalis clinical isolates |
| topic | Trichomonas vaginalis drug resistance nitazoxanide tizoxanide 5-nitroimidazole |
| url | https://journals.asm.org/doi/10.1128/spectrum.02717-24 |
| work_keys_str_mv | AT keontejgraves nitazoxanideandtizoxanidedemonstratehighlevelsofinvitroactivityagainstmetronidazolesusceptibleandmetronidazoleresistanttrichomonasvaginalisclinicalisolates AT johncwilliamson nitazoxanideandtizoxanidedemonstratehighlevelsofinvitroactivityagainstmetronidazolesusceptibleandmetronidazoleresistanttrichomonasvaginalisclinicalisolates AT jannovak nitazoxanideandtizoxanidedemonstratehighlevelsofinvitroactivityagainstmetronidazolesusceptibleandmetronidazoleresistanttrichomonasvaginalisclinicalisolates AT hemantktiwari nitazoxanideandtizoxanidedemonstratehighlevelsofinvitroactivityagainstmetronidazolesusceptibleandmetronidazoleresistanttrichomonasvaginalisclinicalisolates AT wevansecor nitazoxanideandtizoxanidedemonstratehighlevelsofinvitroactivityagainstmetronidazolesusceptibleandmetronidazoleresistanttrichomonasvaginalisclinicalisolates AT christinaamuzny nitazoxanideandtizoxanidedemonstratehighlevelsofinvitroactivityagainstmetronidazolesusceptibleandmetronidazoleresistanttrichomonasvaginalisclinicalisolates |